Background Aims: Cord blood (CB) transplantation slows neurodegeneration during certain inherited metabolic diseases. However, the number of donor cells in the brain of patients does not appear to be sufficient to provide benefit until several months after transplant. We developed the cell product DUOC-01 to provide therapeutic effects in the early post-transplant period.
Methods: DUOC-01 cultures initiated from banked CB units were characterized by use of time-lapse photomicroscopy during the 21-day manufacturing process. Antigen expression was measured by means of flow cytometry and immunocytochemistry; transcripts for cytokines and enzymes by quantitative real-time polymerase chain reaction; activities of lysosomal enzymes by direct biochemical analysis; alloreactivity of DUOC-01 and of peripheral blood (PB) mononuclear cells (MNC) to DUOC-01 by mixed lymphocyte culture methods; and cytokine secretion by Bioplex assays.
Results: DUOC-01 cultures contained highly active, attached, motile, slowly proliferating cells that expressed common (cluster of differentiation [CD]11b, CD14 and Iba1), M1 type (CD16, inducible nitric oxide synthase), and M2-type (CD163, CD206) macrophage or microglia markers. Activities of 11 disease-relevant lysosomal enzymes in DUOC-01 products were similar to those of normal PB cells. All DUOC-01 products secreted interleukin (IL)-6 and IL-10. Accumulation of transforming growth factor-β, IL-1β, interferon-γ and TNF-α in supernatants was variable. IL-12, IL-2, IL-4, IL-5 and IL-13 were not detected at significant concentrations. Galactocerebrosidase, transforming growth factor-β and IL-10 transcripts were specifically enriched in DUOC-01 relative to CB cells. PB MNCs proliferated and released cytokines in response to DUOC-01. DUOC-01 did not proliferate in response to mismatched MNC.
Conclusions: DUOC-01 has potential as an adjunctive cell therapy to myeloablative CB transplant for treatment of inherited metabolic diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843803 | PMC |
| http://dx.doi.org/10.1016/j.jcyt.2015.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and feasibility of umbilical cord blood transplantation in children with neuronal ceroid lipofuscinosis: a retrospective study.
Stem Cells Transl Med
October 2024
Division of Pediatric Transplant and Cellular Therapy, Duke University, 2400 Pratt Street, Box 102502, Durham, NC 27705, United States.
Article Synopsis
- Ceroid lipofuscinosis neuronal (CLN) is a rare neurodegenerative disorder that affects children, causing issues like epilepsy, vision loss, and early death.
- A study analyzed 8 patients with different types of CLN who underwent umbilical cord blood transplant (UCBT) between 2012 and 2020, finding that all patients had successful donor cell engraftment without severe transplant-related deaths.
- Complications like severe graft-versus-host disease and infections were noted, but overall, UCBT showed promise in stabilizing some patients' conditions, highlighting the need for more research and longer follow-up to fully understand its impact.
Cellular Therapies: Yesterday, Today, and Tomorrow.
Stem Cells Dev
April 2023
Oncology Research Unit, Oncology Hospital, IMSS National Medical Center, Mexican Institute of Social Security, Mexico City, Mexico.
Cellular therapy (CT) can be defined as the transference into a person of healthy cells to correct defective functions. (1950-2010), CT consisted mostly of hematopoietic transplants for the treatment of a variety of hematological disorders. Interestingly, during that period of time other cell types with therapeutic potential-including certain lymphoid populations and other nonhematopoietic cells-were discovered and characterized; thus, CT became a promising discipline for the treatment of a broader diversity of diseases.
View Article and Find Full Text PDFGene products promoting remyelination are up-regulated in a cell therapy product manufactured from banked human cord blood.
Cytotherapy
June 2017
Robertson Clinical and Translational Cell Therapy Program, Duke Translational Medicine Institute, Duke University Medical Center, Durham, North Carolina, USA. Electronic address:
Background Aims: DUOC-01, a cell product being developed to treat demyelinating conditions, is composed of macrophages that arise from CD14 monocytes in the mononuclear cell (MNC) population of banked cord blood (CB). This article demonstrates that expression of multiple gene products that promote remyelination is rapidly up-regulated during manufacturing of DUOC-01 from either MNC or purified CB CD14 monocytes.
Methods: Cell cultures were initiated with MNC or with immunoselected CD14 monocytes isolated from the same CB unit.
A cord blood monocyte-derived cell therapy product accelerates brain remyelination.
JCI Insight
August 2016
Robertson Clinical and Translational Cell Therapy Program, Duke Translational Medicine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Microglia and monocytes play important roles in regulating brain remyelination. We developed DUOC-01, a cell therapy product intended for treatment of demyelinating diseases, from banked human umbilical cord blood (CB) mononuclear cells. Immunodepletion and selection studies demonstrated that DUOC-01 cells are derived from CB CD14 monocytes.
View Article and Find Full Text PDFReprint of: Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases.
Cytotherapy
September 2015
Robertson Clinical and Translational Cell Therapy Program, Duke Translational Medicine Institute, Duke University Medical Center, Durham, North Carolina, USA. Electronic address:
Background Aims: Cord blood (CB) transplantation slows neurodegeneration during certain inherited metabolic diseases. However, the number of donor cells in the brain of patients does not appear to be sufficient to provide benefit until several months after transplant. We developed the cell product DUOC-01 to provide therapeutic effects in the early post-transplant period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!